Guidance, NICE advice and quality standards in development | Guidance

Showing 51 to 60 of 391

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]	Technology appraisal guidance	20 February 2019
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]	Technology appraisal guidance	TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]	Technology appraisal guidance	TBC
Bipolar disorder: assessment and management (extraordinary review)	NICE guideline	TBC
Blood transfusion - Tranexamic acid (update)	NICE guideline	26 February 2026
Botulinum toxin type A for preventing episodic migraine [ID6450]	Technology appraisal guidance	TBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]	Technology appraisal guidance	TBC
Breast cancer guidelines	NICE guideline	TBC
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448	Technology appraisal guidance	TBC
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]	Technology appraisal guidance	5 November 2025